Rapid triaging, treatment response assessment and outcome prediction in COVID-19 patients

COVID-19 患者的快速分类、治疗反应评估和结果预测

• 批准号: 54464
• 金额: $ 9.49万
• 依托单位: AINOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=54464
• 关键词: Rapid; triaging; treatment; response; assessment

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. This is also true for COVID-19, where early detection would result in a significantly improved patient prognosis. AINOSTICS' technology represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis and management of patients suffering from COVID-19, using multi-modal clinical imaging and non-imaging data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics.We intend for AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable, quantitative and objective diagnostic data.For serious global diseases, AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes, in addition to making important contributions to the development of disease modifying therapeutics.

在医疗保健方面，及时和个性化的干预对当前和未来对各种疾病的治疗最终有效具有至关重要的作用。新冠肺炎也是如此，早期发现将显著改善患者的预后。AINOSTICS的技术代表着一项突破，它将提供一个自动化、可扩展和个性化的医疗平台，使用多模式临床成像和非成像数据，帮助新冠肺炎患者的临床诊断和管理；我们希望AINOSTICS的软件成为临床实践和药物开发的常规部分，因为我们的智能分析结果将为临床医生、研究人员和成像中心提供一种方便且经济高效的手段，以获得可靠、定量和客观的诊断数据。对于严重的全球疾病，AINOSTICS的技术具有节省患者评估时间、加快临床路径、标准化护理质量和改善患者结果的潜力，此外还为疾病修改疗法的开发做出重要贡献。